Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
in vivo
Biotech
In vivo gene editing biotech blossoms from Jennifer Doudna's lab
Azalea Therapeutics will use the funds to push an in vivo CAR-T therapy for B-cell malignancies into the clinic within the next 12 to 18 months.
Darren Incorvaia
Nov 4, 2025 8:00am
BMS inks $1.5B deal to pull Orbital into its sphere of influence
Oct 10, 2025 8:45am
ARPA-H goes all in on in vivo cell therapy
Oct 8, 2025 4:04pm
Biotech shares first data for in vivo CAR-T that attracted AZ
Jul 7, 2025 2:27pm
Gene editor shelves sole clinical asset, lays off 25% of staff
May 19, 2025 2:28pm
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
May 7, 2025 10:00am
